Previous Close | 0.0468 |
Open | 0.0485 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 0.0485 - 0.0485 |
52 Week Range | 0.0372 - 0.2740 |
Volume | |
Avg. Volume | 71,659 |
Market Cap | 22.198M |
Beta (5Y Monthly) | 1.91 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0840 |
Earnings Date | Jul 14, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for TBPMF
LONDON & MONTREAL, July 12, 2022--Akanda will supply Tetra with pharmaceutical grade cannabis flower in a microdose cap form for global commercialization of Tetra’s QIXLEEF.
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announces the launch of its new wholly owned subsidiary 'Tetra Bio-Pharma Australia Pty Ltd' ("TBP-AU"), an Australian-based research company focused on the execution of clinical trials in Australia. This represents Tetra's second foreign subsidiary and is in line with the Company's global expansion strategy for QIXLEEF™, and other future drug can